$ASMB

Bjorkquist Jeanette M sold $674 of ASMB

Bjorkquist Jeanette M (PFO and PAO) sold 29 shares of ASSEMBLY BIOSCIENCES, INC. (ASMB) at $23.25 on 2026-06-17.

Original reporting
SEC EDGAR · Bjorkquist Jeanette M
Published Jun 18, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ASMB
Neutral
medium confidence
Mentioned
$ASMB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ASMBNeutralLow
01

Why it matters

The newest fact is the specific open-market sale (29 shares at $23.25) and the post-transaction holdings (14,560 shares), with no pre-arranged 10b5-1 plan stated.

02

Market read

Traders may note the filing for sentiment/positioning, but it does not introduce new fundamentals or guidance.

03

What to watch

Insider sales can be driven by taxes, diversification, or pre-existing personal liquidity needs; without additional filings or context, directional inference is weak.

Relevance 3/10Novelty 3/10Timing: after-hours/filing timestamp (2026-06-18) for a 2026-06-17 insider sale

Background

This is an SEC Form 4 insider transaction disclosure for Assembly Biosciences (ASMB) by officer Bjorkquist Jeanette M.

Company-level read

Ticker impact

$ASMBNeutralMedium confidence
Context

Assembly Biosciences disclosed an officer open-market sale of 29 shares at $23.25 on 2026-06-17 via SEC Form 4.

Expected impact

Limited near-term impact; any effect is likely noise unless follow-on insider activity or new fundamentals emerge.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction value ($674) is small and provides no new operating/financial information.

Market effects

No meaningful sector read-through from a small, single insider sale.

None.

None.

Counterpoint

The absence of a 10b5-1 plan could be interpreted as discretionary selling, but the dollar amount is too small to be a strong signal.

Key entities

  • ASSEMBLY BIOSCIENCES, INC.

    Company subject of the insider transaction disclosure on SEC Form 4.

  • Bjorkquist Jeanette M

    Officer who reported the open-market sale of ASMB shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ASMBMedAI 8/10

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

Assembly Biosciences (ASMB) will present Phase 1a data for ABI-6250 at The Liver Meeting 2026. The data shows safety, tolerability, and target engagement, with plans to advance to Phase 2 studies for chronic HDV infection and cholestatic liver diseases. ABI-6250 is an oral NTCP inhibitor. The company aims to initiate Phase 2 studies in Q4 2026 and Q1 2027.

$ASMBHigh

Why is Assembly Biosciences stock surging today?

Assembly Biosciences (ASMB) stock rose 4.9% after hours. The company opted into a 40% share of U.S. profits for its herpes drug program with Gilead Sciences. ASMB could receive $280M in milestones and royalties. The move was driven by company-specific news, not broader market trends. ASMB's cash runway extends into 2029, with a $75M payment from Gilead expected in Q4 2026.

$ASMBMed

ASSEMBLY BIOSCIENCES, INC. (ASMB): Completion of Acquisition or Disposition of Assets

ASSEMBLY BIOSCIENCES, INC. (ASMB) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates – Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 mil